Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.30 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7506112 | 0.89 | GAA (0.46) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL26083007 | 0.86 | GAA (0.43) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL13297030 | 0.85 | CYP2D6 (0.39) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL26083009 | 0.84 | GAA (0.44) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL12368549 | 0.83 | GAA (0.42) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL18237273 | 0.82 | GAA (0.43) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL13660731 | 0.82 | TSHR (0.38) | GAAHTTCYP2D6LMNATSHR | |
| SCHEMBL21236004 | 0.82 | GAA (0.41) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL26083008 | 0.82 | GAA (0.41) | GAAHTTCYP2D6LMNAL3MBTL1 | |
| SCHEMBL4960656 | 0.80 | GAA (0.40) | GAAHTTCYP2D6LMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466130-B2 | Mitochondria targeted cationic anti-oxidant compounds for prevention, therapy or treatment of hyper-proliferative disease, neoplasias and cancers | COLBY PHARMACEUTICAL COMPANY (US) | 2013-06-18 | — | — | US | disclosed |
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | COLBY PHARMACEUTICAL COMPANY (US) | 2011-03-10 | — | — | US | disclosed |
| US-7608659-B2 | Conductive material mixed composition | ADEKA CORPORATION (JP) | 2009-10-27 | — | — | US | disclosed |
| US-20090072204-A1 | CONDUCTIVE MATERIAL MIXED COMPOSITION | ADEKA CORPORATION (JP) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059922-A1 | MITOCHONDRIA TARGETED CATIONIC ANTI-OXIDANT COMPOUNDS FOR PREVENTION, THERAPY OR TREATMENT OF HYPER-PROLIFERATIVE DISEASE, NEOPLASIAS AND CANCERS | TFAM, HSPD1, NLN | GAA 1476/4885HTT 275/4885CYP2D6 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.